Cytisine: The Effective New Drug to Quit Smoking Fast

Cytisine, a medication derived from the Cytisus laburnum plant, is gaining renewed attention as a tool for smoking cessation. While it has been used in eastern Europe since the 1960s, recent reports indicate a surge in demand and expanded accessibility, including reports from Italian outlets such as Il Giunco.net and tagmedicina.it noting that the drug is now covered by the health system and eligible for reimbursement.

The medication works by mimicking the effects of nicotine. According to research published by the National Institutes of Health (NIH) in the Canadian Medical Association Journal (CMAJ), cytisine acts as a partial agonist of the $alpha 4beta 2$ nicotinic acetylcholine receptor, which is the receptor responsible for the central effects of nicotine in the body.

Pharmacokinetics and Treatment Duration

Cytisine offers a different pharmacological profile compared to other cessation aids like varenicline. Data from the NIH indicates that oral cytisine reaches its peak concentration two hours after the dose is administered. It is excreted unchanged renally without hepatic metabolism, a characteristic that lowers the risk of drug interactions.

The treatment course for cytisine is significantly shorter than that of varenicline. While varenicline typically requires a 12-week course, cytisine has a shorter treatment duration of approximately 3.5 weeks. Its half-life is also shorter, measured at 4.8 hours compared to 17 hours for varenicline.

The specific timeline for quitting varies across literature. Some data predicts a 25-day course, while other research published in Tobacco Prevention Cessation describes a 40-day treatment that includes an induction period.

Regulatory Status and Market History

Despite its long-term use in eastern Europe, cytisine did not see widespread regulatory approval in other regions for decades. The NIH notes that the drug’s generic structure made market exclusivity difficult, and its low selling price provided little financial incentive for pharmaceutical companies to pursue the costly regulatory approval processes required in other markets.

Recent developments suggest a shift in the regulatory landscape. Psychiatric Times reports that the FDA has accepted a New Drug Application for cytisinicline, a related drug for smoking cessation that has shown significant abstinence rates in clinical trials.

Safety and Contraindications

Cytisine is not suitable for all patients. The NIH reports that contraindications for the drug include:

• Arterial hypertension
• Advanced atherosclerosis
• Pregnancy
• Breastfeeding

These contraindications were established based on exclusion criteria from cytisine trials, which were derived from the known contraindications of nicotine products.

Public Health Context

The rise in interest in pharmacological aids like cytisine comes amid evolving public health guidelines regarding smoking cessation. For example, Canadian guidelines have indicated that vaping is not a recommended primary method for quitting cigarettes.

The current trend toward cytisine reflects a broader interest in accessible, short-term medical interventions to manage nicotine dependence. In Italy, reports from Il Resto del Carlino suggest a significant increase in interest, noting that requests for the anti-smoking drug have decupled.